Non-cytopathic herpes simplex virus type-1 isolated from acyclovir-treated patients with recurrent infections

Sci Rep. 2022 Jan 25;12(1):1345. doi: 10.1038/s41598-022-05188-w.

Abstract

Herpes simplex virus (HSV) usually produces cytopathic effect (CPE) within 24-72 h post-infection (P.I.). Clinical isolates from recurrent HSV infections in patients on Acyclovir therapy were collected between 2016 and 2019 and tested in cell cultures for cytopathic effects and further in-depth characterization. Fourteen such isolates did not show any CPE in A549 or Vero cell lines even at 120 h P.I. However, these cultures remained positive for HSV-DNA after several passages. Sequence analysis revealed that the non-CPE isolates were all HSV-1. Analysis of the thymidine kinase gene from the isolates revealed several previously reported and two novel ACV-resistant mutations. Immunofluorescence and Western blot data revealed a low-level expression of the immediate early protein, ICP4. Late proteins like ICP5 or capsid protein, VP16 were almost undetectable in these isolates. AFM imaging revealed that the non-CPE viruses had structural deformities compared to wild-type HSV-1. Our findings suggest that these strains are manifesting an unusual phenomenon of being non-CPE herpesviruses with low level of virus protein expressions over several passages. Probably these HSV-1 isolates are evolving towards a more "cryptic" form to establish chronic infection in the host thereby unraveling yet another strategy of herpesviruses to evade the host immune system.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • A549 Cells
  • Acyclovir / pharmacology*
  • Adolescent
  • Adult
  • Aged
  • Animals
  • Antiviral Agents / pharmacology*
  • Chlorocebus aethiops
  • Drug Resistance, Viral / drug effects*
  • Female
  • Herpes Simplex / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Reinfection / drug therapy*
  • Vero Cells
  • Young Adult

Substances

  • Antiviral Agents
  • Acyclovir